Recent developments in the discovery of novel adenosine kinase inhibitors: Mechanism of action and therapeutic potential

CNS Drug Reviews

Volumn 7, Issue 4, 2001, Pages 415-432

  McGaraughty, Steve ^a   Cowart, Marlon ^a   Jarvis, Michael F ^a,b  

^a ABBOTT LABORATORIES   (United States)

^b AP9A/2 ^*  (United States)

Author keywords

A 134974; ABT 702; Adenosine; Adenosine kinase; Analgesia; Epilepsy; Inflammation; P3269; P683

Indexed keywords

4 ANILINO 5 PHENYLPYRROLO[2,3 D]PYRIMIDINE 7 (5 DEOXYRIBOSIDE); A 134974; ABT 702; ADENOSINE KINASE INHIBITOR; ADENOSINE RECEPTOR STIMULATING AGENT; ARISTEROMYCIN; DEOXYADENOSINE; GP 3269; GP 515; GP 947; P 3269; PUROMYCIN; THEOPHYLLINE; TUBERCIDIN DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; DRUG SYNTHESIS; HUMAN; MOUSE; NEUROPROTECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL; RAT; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0035727596     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2001.tb00208.x     Document Type: Review

References (82)

1. The control of the metabolism and the hormonal role of adenosine
2. Structural requirements for activity of nucleosides as substrates for adenosine kinase: Orientation of substituents on the pentafuranosyl ring
3. Metabolic studies with carbocyclic analogs of purine nucleosides
4. Anticonvulsant activity of an adenosine kinase inhibitor, GP 3269 against amygdala-kindled seizures in rats
5. Adenosine involvement in kindled seizures
6. Spinal cord adenosine receptor stimulation in rats inhibits dermal neutrophil accumulation: The role of N-methyl-d-aspartate receptors
7. Anti-inflammatory effects of ABT-702, a novel adenosine kinase inhibitor in rat adjuvant arthritis
8. Site and event specific increase of striatal adenosine release by adenosine kinase inhibition in rats
9. P2 Purinergic receptors: Modulation of cell function and therapeutic potential
10. New adenosine kinase inhibitors with oral antiflammatory activity: Synthesis and biological evaluation
11. Synthesis of novel carbocyclic adenosine analogues as inhibitors of adenosine kinase
12. Structure-activity studies of 5-substituted pyridopyrimidines as adenosine kinase inhibitors
13. SAR of a series of nucleoside analogs as adenosine kinase inhibitors
14. The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine
15. Halogenated pyrrolopyrimidine analogues of adenosine from marine organisms: Pharmacological activities and potent inhibition of adenosine kinase
16. Is adenosine an endogenous anticonvulsant?
17. Adenosine: A potential mediator of seizure arrest and postictal refractoriness
18. Intrinsic tryptophan fluoresence of bovine liver adenosine kinase: Characterization of ligand binding sites and conformational changes
19. Consequences of activation and adenosine mediated inhibition of granulocytes during myocardial ischemia
20. Design, synthesis and anticonvulsant activity of the potent adenosine kinase inhibitor GP3269
21. Therapeutic potential of adenosine kinase inhibitors as analgesic agents
22. An adenosine analogue, 2-chloroadenosine, protects against long term development of ischemic cell loss in the rat hippocampus
23. 2+ wave propagation in dorsal spinal cord astrocytes
24. Protective effect of an adenosine kinase inhibitor in septic shock
25. Anti-inflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation
26. How does adenosine inhibit transmitter release?
27. Adenosine reduces cortical neuronal injury induced by oxygen and glucose deprivation in vitro
28. Adenosine kinase inhibitors augument release of adenosine from spinal cord slices
29. Design of adenosine kinase inhibitors from the NMR-based screening of fragments
30. Substrate binding of adenine nucleosides and nucleotides to certain enzymes
31. Adenosine kinase from human erthrocytes: Kinetic studies and characterization of adenosine binding sites
32. Pyrrolopyrimidine nucleosides. IV. Synthesis of certain 4,5-disubstituted-7-(β-d-ribofuranosyl)pyrrolo[2,3-d]pyrimidines related to the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics
33. Characterization of the antinociceptive effects of some adenosine analogues in the rat
34. ABT-702, a novel orally effective adenosine kinase (AK) inhibitor analgesic with anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in mice
35. Adenosine kinase inhibition protects brain against transient focal ischemia in rats
36. Spinally mediated antinociception is induced in mice by an adenosine kinase, but not an adenosine deaminase inhibitor
37. Adenosine and ATP in epilepsy
38. Adenosine kinase inhibitors
39. Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice
40. Anticonvulsant effects of adenosine kinase inhibitors
41. A-134974, a novel adenosine kinase inhibitor with neuroprotective properties
42. ABT-702, a novel orally effective adenosine kinase (AK) inhibitor analgesic with anti-inflammatory properties. II. Antinociceptive and anti-inflammatory effects in rat models of persistent, inflammatory, and neuropathic pain
43. Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d] pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor
44. Regulation of adenosine kinase by adenosine analogs
45. Inhibition of adenosine kinase during oxygen-glucose deprivation in rat cortical neuronal cultures
46. An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain
47. Structure of human adenosine kinase at 1.5a resolution
48. Effects of A-134974, a novel adenosine kinase (AK) inhibitor, on carrageenan-induced hyperalgesia and locomotor activity in rats: Evaluation of the sites of action
49. Cloning and expression of the adenosine kinase gene from rat and human tissues
50. Therapeutic potential for adenosine receptor activation in ischemic brain injury
51. Pre- and peristroke treatment with the adenosine kinase inhibitor, 5′ deoxyiodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats
52. Adenosine kinase from rabbit liver. II. Substrate and inhibitor specificity
53. Turnover of adenosine in plasma of human and dog blood
54. Acadesine: Prototype adenosine regulating agent for treating myocardial ischemia-reperfusion injury
55. The control of adenosine concentration in polymorphonuclear leukocytes, cultured cells and isolated perfused heart form the rat
56. Adenosine and the concept of "retaliatory metabolites"
57. 1 binding sites after transient forebrain ischemia in the gerbil
58. Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices
59. Synthesis and antiviral properties of (±)-5′-noraristeromycin and related purine carbocyclic nucleosides
60. The adenosine kinase inhibitor, 5-iodotubercidin, is not protective against cerebral ischemic injury in the gerbil
61. Antinociception by adenosine analogs and an adenosine kinase inhibitor: Dependence on formalin concentration
62. Antinociception by adenosine analogs and inhibition of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat
63. Anti-inflammatory effects of an adenosine kinase inhibitor: Decrease neutrophil accumulation and vascular leakage
64. Peripheral antinociceptive effect of an adenosine kinase inhibitor with augmentation by an adenosine deaminase inhibitor, in the rat formalin test
65. Adenosine for pain control
66. Cloning of human adenosine kinase cDNA: Sequence similarity to microbial ribokinases and fructokinases
67. The effect of ABT-702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury
68. Delayed treatment with an adenosine kinase inhibitor, GP 683, attenuates infarct size in rats with temporary middle cerebral artery occlusion
69. Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues
70. Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues
71. Adenosine and acute treatment of cerebral ischemia and stroke - "Put out more flags"
72. The effect of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs
73. Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy
74. Purinergic and pyrimidinergic receptors as potential drug targets
75. Changes in brain adenosine during bicuculline-induced seizures in rats. Effects of hypoxia and altered systemic blood pressure
76. Neuronal plasticity: Increasing the gain in pain
77. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility
78. A-134974, a novel adenosine kinase inhibitor, releives tactile allodynia via spinal sites of action in peripheral nerve injured rats